CINGULATE INC (CING) Stock Price & Overview
NASDAQ:CING • US17248W3034
Current stock price
The current stock price of CING is 5.5 USD. Today CING is down by 0%. In the past month the price decreased by -36.71%. In the past year, price increased by 29.72%.
CING Key Statistics
- Market Cap
- 63.745M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.41
- Dividend Yield
- N/A
CING Stock Performance
CING Stock Chart
CING Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CING. When comparing the yearly performance of all stocks, CING turns out to be only a medium performer in the overall market: it outperformed 64.59% of all stocks.
CING Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CING. Both the profitability and financial health of CING have multiple concerns.
CING Earnings
CING Forecast & Estimates
9 analysts have analysed CING and the average price target is 29.33 USD. This implies a price increase of 433.18% is expected in the next year compared to the current price of 5.5.
CING Groups
Sector & Classification
CING Financial Highlights
Over the last trailing twelve months CING reported a non-GAAP Earnings per Share(EPS) of -4.41. The EPS increased by 76.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -147.32% | ||
| ROE | -885.07% | ||
| Debt/Equity | 2.97 |
CING Ownership
CING Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 878.257B | ||
| JNJ | JOHNSON & JOHNSON | 20.71 | 573.153B | ||
| MRK | MERCK & CO. INC. | 23.52 | 297.058B | ||
| PFE | PFIZER INC | 9.11 | 155.52B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.22 | 118.543B | ||
| ZTS | ZOETIS INC | 17.13 | 50.689B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.45 | 27.937B | ||
| VTRS | VIATRIS INC | 5.6 | 16.104B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.88 | 11.863B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.122B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.497B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.072B | ||
| CORT | CORCEPT THERAPEUTICS INC | 81.05 | 4.606B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CING
Company Profile
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas and currently employs 13 full-time employees. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Company Info
IPO: 2021-10-07
CINGULATE INC
1901 W. 47Th Place
Kansas City KANSAS US
Employees: 14
Phone: 19139422300
CINGULATE INC / CING FAQ
Can you describe the business of CINGULATE INC?
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas and currently employs 13 full-time employees. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
What is the current price of CING stock?
The current stock price of CING is 5.5 USD.
What is the dividend status of CINGULATE INC?
CING does not pay a dividend.
What is the ChartMill technical and fundamental rating of CING stock?
CING has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists CING stock?
CING stock is listed on the Nasdaq exchange.
What is the market capitalization of CING stock?
CINGULATE INC (CING) has a market capitalization of 63.74M USD. This makes CING a Micro Cap stock.
What is the outstanding short interest for CINGULATE INC?
The outstanding short interest for CINGULATE INC (CING) is 14.42% of its float.